Mamoru Shoji

Mamoru Shoji applies creative solutions to the complex challenges of cancer biology, with a particular focus on bone metastasis and tumor angiogenesis. As an Associate Professor Emeritus in the Department of Hematology and Medical Oncology at Emory University School of Medicine, Dr. Shoji has dedicated his career to advancing our understanding of cancer mechanisms and developing innovative targeted therapies. Dr. Shoji's research is centered on the development of therapies that specifically target the blood supply to tumors, aiming to inhibit their growth and spread. His work has been instrumental in the preclinical development and targeted delivery of curcumin analogs, which are explored in combination with other therapeutic agents. This approach has shown promise in disrupting the pathways that tumors use to sustain themselves and metastasize. A significant aspect of Dr. Shoji's research involves investigating the role of tissue factor and vascular endothelial growth factor (VEGF) in cancer. By understanding how these factors contribute to angiogenesis, Dr. Shoji seeks to develop strategies that effectively cut off the nutrient and oxygen supply to tumors, thereby limiting their ability to grow and invade other tissues. Throughout his career, Dr. Shoji has been committed to translating his findings from the laboratory to clinical applications, with the ultimate goal of improving outcomes for patients with cancer. His work not only contributes to the scientific community's understanding of cancer biology but also holds the potential to lead to new, more effective treatments for patients suffering from metastatic cancers. Dr. Shoji's contributions to the field of cancer research have been recognized through numerous publications and presentations at national and international conferences. His dedication to advancing cancer treatment continues to inspire both his colleagues and the next generation of researchers in the field of oncology.